Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial)

Tacchetti P., Beksac M., Dimopoulos M., Zamagni E., Di Raimondo F., Gay F., Hajek R., Marzocchi G., Cellini C., Mellqvist U.H., Johnsen H.E., Ludwig H., Zweegman S., Wester R., Wu K.L., Driessen C., Troia R., Cornelisse P., Van Der Holt B., Palumbo A.Sonneveld P.

Research output: Contribution to journalArticleAcademicpeer-review


The prospective, multicenter, phase III EMN02/HO95 MM trial was designed to randomly compare (R1) (1:1 ratio; stratification by ISS) four 42-day cycles of standard dose bortezomib-melphalan-prednisone (VMP) vs either a single or two sequential courses of melphalan 200 mg/m2 followed by autologous stem cell transplantation (ASCT), as intensification therapy for newly diagnosed multiple myeloma (MM) patients. A second randomization (R2) to consolidation therapy with bortezomib-lenalidomide-dexamethasone vs no consolidation was performed after intensification, to be followed by lenalidomide maintenance until progression or toxicity in both arms. A primary study end point was progression-free survival (PFS) from R1. From February 2011 to April 2014, 1510 patients aged
Original languageEnglish
Pages (from-to)26
Number of pages1
Issue numberSupplement 3
Publication statusPublished - 2017

Cite this